1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 1/20

PUBLICATIONS AUTHORED BY CRISTOBAL BELDA­INIESTA

Veliparib in combination with whole­brain radiation therapy for patients withbrain metastases from non­small cell lung cancer: results of a randomized,

global, placebo­controlled study.J. Neurooncol.J Neurooncol 2016 Sep 21. Epub 2016 Sep 21.Pierre Chabot, Te­Chun Hsia, Jeong­Seon Ryu, Vera Gorbunova,Cristobal Belda­Iniesta, David Ball, EbenezerKio, Minesh Mehta,Katherine Papp, Qin Qin, Jane Qian, Kyle D Holen, Vince Giranda,John H Suh

Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH, 44195, USA.

Veliparib is a potent, orally bioavailable, poly (adenosine diphosphate­ribose) polymerase (PARP)inhibitor that crosses the blood­brain barrier and has been shown to potentiate the effects of radiation inpreclinical and early clinical studies. This phase 2, randomized, global study evaluated the efficacy andsafety of veliparib in combination with whole­brain radiation therapy (WBRT) in patients with brainmetastases from non­small cell lung cancer (NSCLC). Three­hundred and seven patients with brainmetastases from NSCLC were randomized 1:1:1 to WBRT (30 Gy in 10 fractions) plus 50 mg veliparibtwice daily (BID; n = 103), 200 mg veliparib BID (n = 102), or placebo BID (n = 102). Read More

2016Sep

Similar Publications

Cancer stem cells from human glioblastoma resemble but do not mimic originaltumors after in vitro passaging in serum­free media.

OncotargetOncotarget 2016 Aug 29. Epub 2016 Aug 29.Noemí García­Romero, Carmen González­Tejedo, Josefa Carrión­Navarro, Susana Esteban­Rubio, GorjanaRackov, Vanessa Rodríguez­Fanjul, Jorge Oliver­De La Cruz, Ricardo Prat­Acín, María Peris­Celda,David Blesa, LauraRamírez­Jiménez, Pilar Sánchez­Gómez, Rosario Perona, Carmen Escobedo­Lucea, Cristobal Belda­Iniesta, Angel Ayuso­Sacido

Instituto Madrileño de Estudios Avanzados, IMDEA Nanociencia, Madrid, Spain.

Human gliomas harbour cancer stem cells (CSCs) that evolve along the course of the disease, forminghighly heterogeneous subpopulations within the tumour mass. These cells possess self­renewal propertiesand appear to contribute to tumour initiation, metastasis and resistance to therapy. CSC cultures isolatedfrom surgical samples are considered the best preclinical in vitro model for primary humangliomas. Read More

2016Aug

Similar Publications

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 2/20

Efficacy and Safety Results From a Phase II, Placebo­Controlled Study ofOnartuzumab Plus First­Line Platinum­Doublet Chemotherapy for Advanced

Squamous Cell Non­Small­Cell Lung Cancer.Clin Lung CancerClin Lung Cancer 2016 Jun 4. Epub 2016 Jun 4.Fred R Hirsch, Ramaswamy Govindan, Zanete Zvirbule, Fadi Braiteh,Achim Rittmeyer, Cristóbal Belda­Iniesta, DoloresIsla, Thomas Cosgriff, Michelle Boyer, Masamichi Ueda, See Phan, David R Gandara

Division of Hematology­Oncology, University of California Davis Cancer Center, Sacramento, CA.

The treatment options for squamous cell non­small­cell lung cancer (NSCLC) are limited. We assessedthe efficacy and safety of onartuzumab plus platinum­doublet chemotherapy in previously untreatedadvanced squamous cell NSCLC.The patients were randomized to receive onartuzumab plus paclitaxel plus carboplatin/cisplatin (n = 55)or placebo plus paclitaxel plus carboplatin/cisplatin (n = 54). Read More

2016Jun

Similar Publications

g­force induced giant efficiency of nanoparticles internalization into living cells.

Sci RepSci Rep 2015 19;5:15160. Epub 2015 Oct 19.Sandra M Ocampo, Vanessa Rodriguez, Leonor de la Cueva, Gorka Salas, Jose L Carrascosa, María JosefaRodríguez, Noemí García­Romero, Jose Luis F Cuñado, Julio Camarero, Rodolfo Miranda,Cristobal Belda­Iniesta, AngelAyuso­Sacido

Instituto Madrileño de Estudios Avanzados, IMDEA Nanociencia. Madrid, Spain.

Nanotechnology plays an increasingly important role in the biomedical arena. Iron oxide nanoparticles(IONPs)­labelled cells is one of the most promising approaches for a fast and reliable evaluation ofgrafted cells in both preclinical studies and clinical trials. Current procedures to label living cells withIONPs are based on direct incubation or physical approaches based on magnetic or electrical fields,which always display very low cellular uptake efficiencies. Read More

2015Oct

Similar Publications

Biomarkers of erlotinib response in non­small cell lung cancer tumors that do notharbor the more common epidermal growth factor receptor mutations.

2015Jun

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 3/20

Int J Clin Exp PatholInt J Clin Exp Pathol 2015 1;8(3):2888­98. Epub 2015 Mar 1.Blanca D López­Ayllón, Javier de Castro­Carpeño, Carlos Rodriguez,Olga Pernía, Inmaculada Ibañez deCáceres, Cristobal Belda­Iniesta,Rosario Perona, Leandro Sastre

Instituto de Investigaciones Biomédicas CSIC/UAM; Biomarkers and Experimental Therapeutics in Cancer, IdiPaz Madrid, Spain ;CIBER de Enfermedades Raras Valencia, Spain.

Non­small cell lung cancer (NSCLC) represents approximately 85% of all lung cancers, which are theleading cause of cancer­related deaths in the world. Tyrosine kinase inhibitors such as erlotinib representone therapeutic options presently recommended for tumors produced by activating mutations in the genecoding of epidermal growth factor receptor (EGFR). The aim of this study is the identification of possiblebiomarkers for tumor sensitivity to erlotinib in the absence of the main EGFR mutations. Read More

Similar Publications

Methylation status of IGFBP­3 as a useful clinical tool for deciding on aconcomitant radiotherapy.

EpigeneticsEpigenetics 2014 Nov;9(11):1446­53Olga Pernía, Cristobal Belda­Iniesta, Veronica Pulido, María Cortes­Sempere, Carlos Rodriguez, Olga Vera, JavierSoto, Julia Jiménez,Alvaro Taus, Federico Rojo, Edurne Arriola, Ana Rovira, Joan Albanell,M Teresa Macías, Javier deCastro, Rosario Perona, Inmaculada Ibañez de Caceres

a Cancer Epigenetics Laboratory, INGEMM ; University Hospital La Paz ; Madrid , Spain.

The methylation status of the IGFBP­3 gene is strongly associated with cisplatin sensitivity in patientswith non­small cell lung cancer (NSCLC). In this study, we found in vitro evidence that linked thepresence of an unmethylated promoter with poor response to radiation. Our data also indicate thatradiation might sensitize chemotherapy­resistant cells by reactivating IGFBP­3­expression throughpromoter demethylation, inactivating the PI3K/AKT pathway. Read More

2014Nov

Similar Publications

Cancer stem cells and cisplatin­resistant cells isolated from non­small­lungcancer cell lines constitute related cell populations.

Cancer MedCancer Med 2014 Oct 25;3(5):1099­111. Epub 2014 Jun 25.Blanca D Lopez­Ayllon, Veronica Moncho­Amor, Ander Abarrategi,Inmaculada Ibañez de Cáceres, Javier Castro­Carpeño, Cristobal Belda­Iniesta, Rosario Perona, Leandro Sastre

Instituto de Investigaciones Biomédicas CSIC/UAM, Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Spain.

2014Oct

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 4/20

Lung cancer is the top cause of cancer­related deceases. One of the reasons is the development ofresistance to the chemotherapy treatment. In particular, cancer stem cells (CSCs), can escape treatmentand regenerate the bulk of the tumor. Read More

Similar Publications

SOX2+ cell population from normal human brain white matter is able togenerate mature oligodendrocytes.

PLoS ONEPLoS One 2014 5;9(6):e99253. Epub 2014 Jun 5.Jorge Oliver­De La Cruz, Josefa Carrión­Navarro, Noemí García­Romero, Antonio Gutiérrez­Martín, Elisa Lázaro­Ibáñez, Carmen Escobedo­Lucea, Rosario Perona, Cristobal Belda­Iniesta, Angel Ayuso­Sacido

Centro Integral Oncológico Clara Campal (CIOCC) and Instituto de Medicina Molecular Aplicada (IMMA), Hospital de MadridFoundation, Madrid, Spain; Division of Biopharmaceuticals and Pharmacokinetics, University of Helsinki, Helsinki, Finland;Nanomedicine Laboratory, Instituto Madrileño de Estudios Avanzados IMDEA nanoscience, Madrid, Spain.

A number of neurodegenerative diseases progress with a loss of myelin, which makes them candidatediseases for the development of cell­replacement therapies based on mobilisation or isolation of theendogenous neural/glial progenitor cells, in vitro expansion, and further implantation. Cells expressingA2B5 or PDGFRA/CNP have been isolated within the pool of glial progenitor cells in the subcorticalwhite matter of the normal adult human brain, all of which demonstrate glial progenitor features.However, the heterogeneity and differentiation potential of this pool of cells is not yet wellestablished. Read More

2014Jun

Similar Publications

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeuticapproach.

Transl Lung Cancer ResTransl Lung Cancer Res 2013 Apr;2(2):142­51Javier de Castro Carpeño, Cristóbal Belda­Iniesta

Thoracic, H&N and Neuro­oncology Unit, CIOCC, GHM, Madrid, Spain.

K­RAS accounts for 90% of RAS mutations in lung adenocarcinomas, the most commonly mutatedoncogene in NSCLC, with mutations detected in about 25% of all tumors. Direct inhibition of KRAS has

2013Apr

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 5/20

proven clinically challenging. So far, no successful targeted therapy has been developed and remains anelusive target for cancer therapy. Read More

Similar Publications

The ALK translocation in advanced non­small­cell lung carcinomas:preapproval testing experience at a single cancer centre.

HistopathologyHistopathology 2013 Mar 5;62(4):609­16. Epub 2013 Feb 5.Esther Conde, Bárbara Angulo, Elisa Izquierdo, Luna Muñoz, Ana Suárez­Gauthier, Carlos Plaza, NuriaDominguez, Maribel Torres, Luis Madrigal, Belén Rubio­Viqueira, Cristobal Belda­Iniesta, Manuel Hidalgo, FernandoLópez­Ríos

Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid Sanchinarro,Universidad San Pablo­CEU, Madrid, Spain.

To study the ALK translocation in patients with advanced non­small­cell lung carcinomas (NSCLCs)seen at a European cancer centre, and its association with EGFR mutations, KRAS mutations and METamplification.The study included samples from 86 patients diagnosed with advanced NSCLC. ALK fluorescence in­situ hybridization (FISH) was performed using the ALK break­apart probe set (Vysis). Read More

2013Mar

Similar Publications

Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy isan adverse prognostic factor and a potential therapeutic target.

Int. J. Radiat. Oncol. Biol. Phys.Int J Radiat Oncol Biol Phys 2012 Dec 18;84(5):1151­8. Epub 2012 Apr 18.Enrique Casado, Victor Moreno Garcia, Jose Javier Sánchez, María Teresa Gómez Del Pulgar, Jaime Feliu, JoanMaurel, Beatriz Castelo,Juan Moreno Rubio, Rocío A B López, Miguel Ángel García­Cabezas,Emilio Burgos, Javier deCastro, Cristóbal Belda­Iniesta, Miriam López­Gómez, César Gómez­Raposo, Francisco Zambrana, María Sereno, CarlosFernández­Martos, Pilar Vázquez, Juan Carlos Lacal,Manuel González­Barón, Paloma Cejas

Unidad de Oncología, Hospital Infanta Sofía, Madrid, Spain.

Management of locally advanced rectal cancer (RC) consists of neoadjuvant chemoradiotherapy (CRT)with fluoropyrimidines, followed by total mesorectal excision. We sought to evaluate the expression ofselected genes, some of which were derived from a previous undirected SAGE (serial analysis of geneexpression)­based approach, before and after CRT, to identify mechanisms of resistance.This retrospective cohort study included 129 consecutive patients. Read More

2012Dec

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 6/20

Similar Publications

Cost­effectiveness, cancer burden and financial crisis: a perfect storm.

Clin Transl OncolClin Transl Oncol 2012 Oct 21;14(10):713­4. Epub 2012 Sep 21.Cristobal Belda­Iniesta

Read More

2012Oct

Similar Publications

Foot pain: uncommon presentation of lung cancer.

BMJ Case RepBMJ Case Rep 2012 13;2012. Epub 2012 Jul 13.Angela Lamarca, Nadia Hindi, Cristobal Belda­Iniesta, Javier de Castro

Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain.

Acrometastases is an unusual presentation of bone metastases, specially when they are the uniquelocation of bone metastases. The authors report a case of a men diagnosed with a lung adenocarcinomawith a unique lytic acrometastases in his left foot. He has been treated with systemic chemotherapy withgood local and systemic response. Read More

2012Jul

Similar Publications

ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic andpredictive implications.

Int. J. Oncol.Int J Oncol 2012 Jun 16;40(6):2104­10. Epub 2012 Feb 16.Maria Sereno, Paloma Cejas, Víctor Moreno, Cristóbal Belda­Iniesta,Rocio López, Manuel Nistal, Jaime Feliu, Javier DeCastro Carpeño

Department of Medical Oncology, Infanta Sofía Hospital, 28702 San Sebastian De Los Reyes, Madrid, Spain.

2012Jun

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 7/20

Small cell lung cancer is the most aggressive lung cancer subtype. The standard treatment approach isbased on cisplatin regimens. Although response rates to treatment are approximately 60­80%, the mediansurvival is still very poor. Read More

Similar Publications

Insulin therapy in diabetes and cancer risk: current understanding andimplications for future study: proceedings from a meeting of a European Insulin

Safety Consensus Panel, convened and sponsored by Novo Nordisk, held TuesdayOctober 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UK.Adv TherAdv Ther 2011 Sep 19;28 Suppl 5:1­18. Epub 2011 Aug 19.Stephen C L Gough, Cristóbal Belda­Iniesta, Christopher Poole,Matthias Weber, David Russell­Jones, Bo FalckHansen, Edoardo Mannucci, Jaakko Tuomilehto

Oxford Centre for Diabetes Endocrinology and Metabolism and Oxford, NIHR, Biomedical Research Centre, Churchill Hospital,Oxford OX3 7LJ, UK.

Interest in the possibility of certain insulin treatments having the potential to modify cancer developmentand prognosis was reawakened in 2009, following publication of several epidemiological studiesaddressing this issue. This interest extends to how diabetes itself and cancer might be linked, and makesdesirable an exchange of expert views and knowledge to enhance understanding in this subject amongthose treating diabetes and cancer, or those developing diabetes therapies.A European meeting was convened with participants invited based on known relevant interests inendocrinology, oncology, epidemiology, and insulin analog design and investigation. Read More

2011Sep

Similar Publications

A combined strategy of SAGE and quantitative PCR Provides a 13­genesignature that predicts preoperative chemoradiotherapy response and outcome

in rectal cancer.Clin. Cancer Res.Clin Cancer Res 2011 Jun 5;17(12):4145­54. Epub 2011 Apr 5.Enrique Casado, Victor Moreno García, Jose Javier Sánchez,Montserrat Blanco, Joan Maurel, Jaime Feliu, CarlosFernández­Martos, Javier de Castro, Beatriz Castelo, Cristóbal Belda­Iniesta,María Sereno, Benito Sánchez­Llamas, Emilio Burgos, Miguel Ángel García­Cabezas, Noemí Manceñido, Rosa Miquel, Damián García­Olmo, ManuelGonzález­Barón, Paloma Cejas

Unidad de Oncología; Unidad de Gastroenterología, Hospital Infanta Sofía, Spain.

2011Jun

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 8/20

Preoperative chemoradiotherapy (CRT) is the treatment of choice for rectal cancer (RC), but half of thepatients do not respond, suffer unnecessary toxicities, and surgery delays. We aimed to develop a modelthat could predict a clinically meaningful response to CRT by using formalin­fixed paraffin­embedded(FFPE) biopsies.We first carried out an exploratory screening of candidate genes by using SAGE technology to evaluatedynamic changes in the RC transcriptome in selected refractory patients before and after CRT. ReadMore

Similar Publications

Metformin: a new option in cancer treatment.

Clin Transl OncolClin Transl Oncol 2011 Jun;13(6):363­7Cristóbal Belda­Iniesta, Olga Pernía, Rafael Simó

Biomarkers and Experimental Therapeutics of Cancer Group, IdiPAZ, University Hospital La Paz, Madrid, Spain.

Metformin is a biguanine, the most widely used antidiabetic drug for the treatment of type 2 diabetes.Some studies suggest that metformin decreases the incidence of cancer and cancer­related mortality indiabetic patients. Metformin activates the AMP­activated protein kinase (AMPK) pathway, a major sensorof the energy status of the cell and an inhibitor of mammalian target of rapamycin (mTOR) catalyticactivity, inducing a decrease in blood glucose by decreasing hepatic gluconeogenesis and stimulatingglucose uptake in the muscle. Read More

2011Jun

Similar Publications

A role for cancer stem cells in drug resistance and metastasis in non­small­celllung cancer.

Clin Transl OncolClin Transl Oncol 2011 May;13(5):289­93Rosario Perona, Blanca D López­Ayllón, Javier de Castro Carpeño,Cristóbal Belda­Iniesta

Instituto de Investigaciones Biomédicas CSIC/UAM, CIBER de Enfermedades Raras, IdiPAZ, Madrid, Spain.

The cancer stem cell (CSC) theory is currently a very important field in cancer research. This theorystates that tumours are organised in a hierarchical manner with a subpopulation of limited number called

2011May

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 9/20

CSCs with the ability to self­renew and undergo asymmetrical divisions, giving rise to a differentiatedprogeny that represents most of the tumour populations. CSCs are metastatic and chemoresistant, twofeatures that very likely contribute to the poor response of locally advanced lung cancer. Read More

Similar Publications

Monoclonal antibodies for medical oncology: a few critical perspectives.

Clin Transl OncolClin Transl Oncol 2011 Feb;13(2):84­7Cristóbal Belda­Iniesta, Inmaculada Ibáñez de Cáceres, Javier de Castro

Biomarkers and Experimental Therapeutics Group, IdiPAZ, University Hospital La Paz, Madrid, Spain.

Incorporation of antibodies as weapons for cancer therapy has meant a turning point in the survival,clinical and radiological response of many oncology patients. These drugs are effective, well designedmissiles that either alone or in combination with chemotherapy are unavoidable weapons for breast, lungand colon cancer as well as for haematological tumours. In addition, incoming monoclonal antibodies(mAbs) and folder­like proteins will be incorporated into clinical practice in the near future. Read More

2011Feb

Similar Publications

Translational proteomics: what can you do for true patients?

J. Proteome Res.J Proteome Res 2011 Jan 7;10(1):101­4. Epub 2010 Dec 7.Cristobal Belda­Iniesta, Javier de Castro, Rosario Perona

Biomarkers and Experimental Therapeutics for Cancer Group, IdiPAZ, University Hospital La Paz, Madrid, Spain.

Matching the right medical strategy to the right patient is the key for modern clinical oncology. To thisaim, we have many delicate drugs designed to target in elegant ways critical proteins identified in cancercells. However, clinical oncologists and multidisciplinary groups devoted to treating patients in anintegrative fashion have histology and an TNM staging system as the most relevant biomarkers to decidetherapeutic approaches for our patients. Read More

2011Jan

Similar Publications

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 10/20

Suppressing glioblastoma stem cell function by aldehyde dehydrogenaseinhibition with chloramphenicol or disulfiram as a new treatment adjunct: an

hypothesis.Curr Stem Cell Res TherCurr Stem Cell Res Ther 2009 Dec;4(4):314­7Richard E Kast, Cristobal Belda­Iniesta

University of Vermont, 2 Church Street, Burlington, VT 05401, USA.

Strong expression of aldehyde dehydrogenase is a prominent feature of both normal and cancer stemcells, including the stem cell sub­population of glioblastoma. Aldehyde dehydrogenase function is usedby cancer stem cells to repopulate a tumor mass after chemotherapy cytoreduction. Cancer stem cellstend to be chemotherapy compared to the non­stem cell majority cell population in several commonhuman cancers. Read More

2009Dec

Similar Publications

MKP1 repression is required for the chemosensitizing effects of NF­kappaB andPI3K inhibitors to cisplatin in non­small cell lung cancer.

Cancer Lett.Cancer Lett 2009 Dec 23;286(2):206­16. Epub 2009 Jun 23.María Cortes­Sempere, Sharmila Chattopadhyay, Ana Rovira, Vanessa Rodriguez­Fanjul, Cristobal Belda­Iniesta, MarianTapia, Paloma Cejas,Rosario Machado­Pinilla, Cristina Manguan­García, Isabel Sánchez­Pérez, Manuel Nistal, CarmenMoratilla, Javier de Castro­Carpeño,Manuel Gonzalez­Barón, Joan Albanell, Rosario Perona

Translational Oncology Unit C.S.I.C./U.A.M: Instituto de Investigaciones Biomédicas C.S.I.C./U.A.M., Madrid 28029, Spain.

Treatment of non­small cell lung cancer (NSCLC) with cisplatin has a level of antitumor activity stillmodest. We have shown previously that MKP1/DUSP1 inhibits cisplatin­induced apoptosis in NSCLCcells and is overexpressed in tumors from most patients with stage I­II NSCLC. Here, using differentNSCLC cell lines we found that MKP1 and NF­kappaB are differentially expressed. Read More

2009Dec

Similar Publications

KRAS mutations in primary colorectal cancer tumors and related metastases: apotential role in prediction of lung metastasis.

PLoS ONEPLoS One 2009 18;4(12):e8199. Epub 2009 Dec 18.

2009Dec

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 11/20

Paloma Cejas, Miriam López­Gómez, Cristina Aguayo, Rosario Madero, Javier de Castro Carpeño, Cristóbal Belda­Iniesta, Jorge Barriuso, Víctor Moreno García, Javier Larrauri, Rocío López, Enrique Casado, Manuel Gonzalez­Barón, Jaime Feliu

Department of Medical Oncology, La Paz University Hospital, Madrid, Spain.

KRAS mutations in colorectal cancer primary tumors predict resistance to anti­Epidermal Growth FactorReceptor (EGFR) monoclonal antibody therapy in patients with metastatic colorectal cancer, and thusrepresent a true indicator of EGFR pathway activation status.KRAS mutations were retrospectively studied using polymerase chain reactions and subsequentsequencing of codons 12 and 13 (exon 2) in 110 patients with metastatic colorectal tumors. These studieswere performed using tissue samples from both the primary tumor and their related metastases (93 liver,84%; 17 lung, 16%). Read More

Similar Publications

Clinical impact of aneuploidy on gastric cancer patients.

Clin Transl OncolClin Transl Oncol 2009 Aug;11(8):493­8Isabel Sánchez­Pérez, Pilar García Alonso, Cristóbal Belda Iniesta

Translational Oncology Unit CSIC/UAM, Instituto de Investigaciones Biomédicas CSIC/UAM, Madrid, Spain.

Gastric cancer is a leading cause of death worldwide. Nowadays, complete surgical resection and TNMat diagnosis are the main prognostic factors. In spite of this, many patients will have a recurrence aftersurgery and die within a few months or years. Read More

2009Aug

Similar Publications

Complete and rapid response to FOLFIRI plus bevacizumab in a patientpresenting with impaired liver function and poor performance status from colon

cancer liver metastases.Anticancer DrugsAnticancer Drugs 2009 Apr;20 Spec No 1:S11­2Cristóbal Belda­Iniesta, Enrique Casado Sáenz, Javier de Castro­Carpeño, Elena Hernández, Manuel González Barón

aMedical Oncology Division, University Hospital La Paz, School of Medicine, Autonomous University of Madrid, Madrid bMDAnderson Cancer Center International, Madrid, Spain.

2009Apr

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 12/20

Impaired liver function is a final complication of hepatic metastases from colon cancer. This diseasestatus is of critical importance at first clinical presentation because of the tight therapeutic window forchemotherapy. A rapid response to treatment is required as other means of supportive care for hepaticfunction are limited. Read More

Similar Publications

The combination of FOLFOX4 and bevacizumab may enable salvage surgery ofunresectable liver metastases in colon cancer.

Anticancer DrugsAnticancer Drugs 2009 Apr;20 Spec No 1:S4­6María Sereno Moyano, Enrique Casado Sáenz, Javier de Castro­Carpeño, Cristóbal Belda­Iniesta

Medical Oncology Department, Hospital Infanta Sofía, Madrid, Spain.

Colorectal cancer treatment has experienced important advances in the last 5 years. New targetedtherapies have been included in the classical regimens based on 5­fluorouracil, oxaliplatin, or irinotecan.This new approach has brought great revolution in the treatment of this type of cancer. Read More

2009Apr

Similar Publications

Bevacizumab: a safe and effective treatment in a patient with advancedcolorectal cancer and repeated removal of metastases.

Anticancer DrugsAnticancer Drugs 2009 Apr;20 Spec No 1:S7­S10Javier de Castro­Carpeño, María Sereno Moyano, Enrique Casado Sáenz, Cristóbal Belda­Iniesta, Jaime FeliuBatlle, Manuel González Barón

Department of Medical Oncology, La Paz University Hospital, Madrid Autonomous University, Madrid, Spain.

Bevacizumab has been shown to be effective combined with chemotherapy for first­line treatment ofadvanced colorectal cancer, but little information is available about its efficacy and safety in patients whomay be candidates for surgery at any time during the disease. The case history of a female patient withcolorectal cancer, undergoing surgery for liver metastases and bilateral surgery for lung metastases atdifferent time­points during her disease, is reported. Perioperative bevacizumab administration caused nocomplications either associated with surgery, in the early postoperative period, or in the subsequentmonths. Read More

2009Apr

Similar Publications

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 13/20

EPO­R expression patterns in resected gastric adenocarcinoma followed byadjuvant chemoradiation treatment.

Pathol. Oncol. Res.Pathol Oncol Res 2009 Mar 11;15(1):1­10. Epub 2008 Nov 11.Maria Sereno, Javier De Castro, Cristóbal Belda­Iniesta, Miguel Angel Garcia­Cabezas, Paloma Cejas, EnriqueCasado, Jorge Barriuso, Jaime Feliu, Javier Larrauri

Medical Oncology Division, Infanta Sofía Hospital, San Sebastian de los Reyes, Madrid, Spain.

The primary aim was to determine whether Epo­R immunohistochemical expression is related to diseasefree survival (DFS) in specimens of GC from patients who underwent adjuvant chemoradiation.Specimens of gastric adenocarcinomas obtained from 44 patients who had undergone curativegastrectomy and adjuvant treatment were investigated immunohistochemically expression of Epo­R.Three patterns for Epo­R staining were defined: Pattern A (secretory cells­like staining), Pattern B(parietal­like staining) and Pattern C (chief­like staining). Read More

2009Mar

Similar Publications

Combination therapy with docetaxel and low dose of cisplatin in elderly patientswith advanced non­small cell lung cancer: multicenter phase II study.

Cancer Chemother. Pharmacol.Cancer Chemother Pharmacol 2009 Feb 9;63(3):403­9. Epub 2008 Apr 9.Jaime Feliu, Jose Luis Firvida, Javier Castro, Catherina Madroñal,Angeles Rodríguez­Jaráiz, Mercedes Salgado, CristóbalBelda­Iniesta,Enrique Casado, Jesús García­Mata, Manuel González­Barón,

Medical Oncology Service, La Paz Hospital, P masculine de la Castellana, Madrid, Spain.

To determine the efficacy and safety of the combination therapy with docetaxel and cisplatin (CDDP) atlow doses in elderly patients with advanced NSCLC.A total of 42 patients aged > or =70 years with previously untreated advanced NSCLC receiveddocetaxel 75 mg/m(2) plus CDDP 50 mg/m(2) on day 1. The regimen was repeated every 21 days. ReadMore

2009Feb

Similar Publications

Molecular biology of pancreatic cancer.2008Sep

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 14/20

Clin Transl OncolClin Transl Oncol 2008 Sep;10(9):530­7Cristóbal Belda­Iniesta, Immaculada Ibáñez de Cáceres, Jorge Barriuso, Javier de Castro Carpeño, Manuel GonzálezBarón, Jaime Feliú

Translational Oncology Unit CSIC/JAM at Medical Oncology Division, University Hospital La Paz, Universidad Autónoma de Madrid,Madrid, Spain.

Pancreatic cancer is a leading cause of cancer death. This devastating disease has the horrible honour ofclose to equal incidence and mortality rates. Late diagnosis and a constitutive resistance to everychemotherapy approach are responsible for this scenario. Read More

Similar Publications

Role of CHK2 in cancer development.

Clin Transl OncolClin Transl Oncol 2008 Sep;10(9):538­42Rosario Perona, Verónica Moncho­Amor, Rosario Machado­Pinilla,Cristóbal Belda­Iniesta, Isabel Sánchez Pérez

Instituto de Investigaciones Biomédicas C.S.I.C./U.A.M., Madrid, Spain.

DNA repair pathways enable tumour cells to survive DNA damage induced by external agents such astherapeutic treatments. Signalling cascades involved in these pathways comprise the DNA­dependentprotein kinase (DNA­PK), Ataxia­telangiectasia mutated (ATM), ATM and Rad3 related (ATR) andcheckpoint kinases I and 2 (Chk1/Chk2), among others. ATM and ATR phosphorylate, respectively,Chk2 and Chk1, leading to activation of checkpoints. Read More

2008Sep

Similar Publications

Retroperitoneal Castleman's disease with colon cancer. A rare association.

Clin Transl OncolClin Transl Oncol 2008 Apr;10(4):238­40César Gómez­Raposo, Manuel Nistal, Javier De Castro Carpeño,Grevelyn Sosa Rotundo, Cristóbal Belda­Iniesta, EnriqueCasado,Manuel González Barón

Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain.

2008Apr

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 15/20

Castleman's disease (CD) is a rare disorder of uncertain aetiology characterised by massive proliferationof lymphoid tissue usually localised as mediastinal masses, although abdominal involvement has beenreported. Localised forms are usually associated with a good prognosis, but several more aggressivemultifocal variants have been observed. Two different histologic subtypes have been described: thehyaline vascular type, more common in unicentric CD and usually asymptomatic, and the plasma cellform. Read More

Similar Publications

Early intervention with epoetin beta prevents severe anaemia in lung cancerpatients receiving platinum­based chemotherapy: a subgroup analysis of the

NeoPrevent study.Lung CancerLung Cancer 2008 Feb 17;59(2):211­8. Epub 2007 Sep 17.Javier de Castro, Cristóbal Belda­Iniesta, Dolores Isla, Manuel Dómine, Alfredo Sánchez, Eduard Batiste, ManuelGonzález Barón

Servicio de Oncología Médica, Hospital Universitario La Paz (Madrid), Paseo de la Castellana, 261, 28046 Madrid, Spain.

The NeoPrevent study showed that early intervention with epoetin beta could prevent severe anaemia inpatients with solid tumours receiving platinum­based chemotherapy. An early intervention strategy maybe particularly warranted in patients with lung cancer, as anaemia is very common in these patients andcan be severe. The purpose of this study was to examine the efficacy and safety of epoetin beta in thesubpopulation of patients with lung cancer included in the NeoPrevent study. Read More

2008Feb

Similar Publications

Epidermal growth factor receptor and glioblastoma multiforme: molecular basisfor a new approach.

Clin Transl OncolClin Transl Oncol 2008 Feb;10(2):73­7Cristóbal Belda­Iniesta, Javier de Castro Carpeño, María Sereno,Manuel González­Barón, Rosario Perona

Translational Oncology Unit (CSIC/UAM) at Medical Oncology Division, University Hospital La Paz, Universidad Autonoma deMadrid, Madrid, Spain.

High­grade gliomas are the most common primary malignant brain tumours. Surgery, radiotherapy andchemotherapy are the cornerstone of actual treatment. In spite of large therapeutic efforts, overallsurvival is still poor. Read More

2008Feb

Similar Publications

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 16/20

Expression of choline kinase alpha to predict outcome in patients with early­stage non­small­cell lung cancer: a retrospective study.

Lancet Oncol.Lancet Oncol 2007 Oct;8(10):889­97Ana Ramírez de Molina, Jacinto Sarmentero­Estrada, Cristóbal Belda­Iniesta, Miquel Tarón, Victor Ramírez deMolina, Paloma Cejas, Marcin Skrzypski, David Gallego­Ortega, Javier de Castro, Enrique Casado,Miguel Angel García­Cabezas, Jose Javier Sánchez, Manuel Nistal,Rafael Rosell, Manuel González­Barón, Juan Carlos Lacal

Translational Oncology Unit, CSIC­UAM­La Paz, National Center of Biotechnology, Madrid, Spain.

Adequate prognostic markers to predict outcome of patients with lung cancer are still needed. The aim ofthis study was to assess whether choline kinase alpha (ChoKalpha) gene expression could identifypatients with different prognoses. ChoKalpha is an enzyme involved in cell metabolism and proliferationand has a role in oncogene­mediated transformation in several human tumours, including lungcancer. Read More

2007Oct

Similar Publications

Human recombinant erythropoietin does not promote cancer growth in presenceof functional receptors expressed in cancer cells.

Cancer Biol. Ther.Cancer Biol Ther 2007 Oct 12;6(10):1600­5. Epub 2007 Jul 12.Cristóbal Belda­Iniesta, Rosario Perona, Javier de Castro Carpeño,Paloma Cejas, Enrique Casado, Cristina Manguan­García, Inmaculada Ibanez de Caceres, Isabel Sanchez­Perez, Francisco Bernabeu Andreu,Javier Alves Ferreira, AlfredoAguilera, Javier de la Peña, Elia Perez­Sánchez, Rosario Madero, Jaime Feliu, María Sereno, Manuel González­Barón

Translational Oncology Unit (CSIC/UAM), Medical Oncology Division, Hospital Universitario La Paz, Universidad Autónoma deMadrid, Madrid, Spain.

Human recombinant erythropoietin (hrEPO) therapy might be associated with tumor progression anddeath. This effect has been suggested to be secondary to rhEPO binding to its receptor (EPOR) expressedon cancer cells. However, there are several concerns about EPOR functionality when expressed oncancer cells. Read More

2007Oct

Similar Publications

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 17/20

Molecular biology of malignant gliomas.

Clin Transl OncolClin Transl Oncol 2006 Sep;8(9):635­41Cristóbal Belda­Iniesta, Javier de Castro Carpeño, Enrique Casado Sáenz, Paloma Cejas Guerrero, Rosario Perona, ManuelGonzález Barón

Translational Oncology Unit (CSIC/UAM) at Medical Oncology Division, Hospital Universitario La Paz, Universidad Autónoma deMadrid, Spain.

Gliomas are the most common primary brain tumours. In keeping with the degree of aggressiveness,gliomas are divided into four grades, with different biological behaviour. Furthermore, as differentgliomas share a predominant histological appearance, the final classification includes both, histologicalfeatures and degree of malignancy. Read More

2006Sep

Similar Publications

Long term responses with cetuximab therapy in glioblastoma multiforme.

Cancer Biol. Ther.Cancer Biol Ther 2006 Aug 23;5(8):912­4. Epub 2006 Aug 23.Cristóbal Belda­Iniesta, Javier de Castro Carpeño, Enrique Casado Saenz, Manuel Gutiérrez, Rosario Perona, ManuelGonzález Barón

Translational Oncology Unit CSIC­UAM, Medical Oncology Division, Hospital Universitario La Paz, Universidad Autonoma deMadrid, Madrid, Spain.

Glioblastoma multiforme (GBM) is responsible for most of the deaths associated with primary braintumors. Standard treatment includes maximal surgical resection followed by chemotherapy andconcomitant radiotherapy. Most patients, however, recur shortly after treatment. Read More

2006Aug

Similar Publications

Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markersof cancer prognosis.

CarcinogenesisCarcinogenesis 2005 Dec 20;26(12):2095­104. Epub 2005 Jul 20.Antonio Isidoro, Enrique Casado, Andrés Redondo, Paloma Acebo,Enrique Espinosa, Andrés M Alonso, PalomaCejas, David Hardisson,Juan A Fresno Vara, Cristobal Belda­Iniesta, Manuel González­Barón,José M Cuezva

Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, Spain.

2005Dec

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 18/20

The aim of this study was to investigate selected proteomic markers of the metabolic phenotype of breastcarcinomas as prognostic markers of cancer progression. For this purpose, a series of 101 breastcarcinomas and 13 uninvolved breast samples were examined for quantitative differences in proteinexpression of mitochondrial and glycolytic markers. The beta­subunit of the mitochondrial H(+)­ATPsynthase (beta­F1­ATPase) and heat shock protein 60 (Hsp60), and the glycolytic glyceraldehyde­3­phosphate dehydrogenase, pyruvate kinase and lactate dehydrogenase were identified by immunologicaltechniques. Read More

Similar Publications

Subacute dementia as presenting feature of carcinomatous leptomeningealmetastases.

Clin Transl OncolClin Transl Oncol 2005 Jan­Feb;7(1):29­30María Sereno Moyano, Enrique Casado Saenz, Cristóbal Belda Iniesta,Manuel González Barón

Servicio de Oncología Médica, Hospital de La Paz, Madrid, Spain.

Read More

2005May

Similar Publications

Implications of oxidative stress and cell membrane lipid peroxidation in humancancer (Spain).

Cancer Causes ControlCancer Causes Control 2004 Sep;15(7):707­19Paloma Cejas, Enrique Casado, Cristobal Belda­Iniesta, Javier De Castro, Enrique Espinosa, Andrés Redondo, MaríaSereno, Miguel A García­Cabezas, Juan A F Vara, Aurora Domínguez­Cáceres, Rosario Perona, Manuel González­Barón

Cátedra de Oncología y Medicina Paliativa, Servicio de Oncología Médica, Unidad de Oncología Molecular, Hospital Universitario LaPaz, Madrid, Spain.

Reactive Oxygen Species (ROS) result from cell metabolism as well as from extracellular processes. ROSexert some functions necessary for cell homeostasis maintenance. When produced in excess they play arole in the causation of cancer. Read More

2004Sep

Similar Publications

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 19/20

Do beta­tubulin pseudogenes really matter?

Lancet Oncol.Lancet Oncol 2004 May;5(5):271­2Cristobal Belda­Iniesta, Rosario Perona, Javier de Castro Carpeno,Sharmila Chattopadhyay, Enrique Casado, PalomaCejas, Juan Angel Fresno Vara, Concepcion Moreno Guerra, Manuel Gonzalez Baron

Read More

2004May

Similar Publications

PI3K/Akt signalling pathway and cancer.

Cancer Treat. Rev.Cancer Treat Rev 2004 Apr;30(2):193­204Juan Angel Fresno Vara, Enrique Casado, Javier de Castro, Paloma Cejas, Cristóbal Belda­Iniesta, Manuel González­Barón

Cátedra de Oncología y Medicina Paliativa, Servicio de Oncología Médica, Hospital Universitario La Paz, Paseo de la Castellana 261,Madrid 28046, Spain.

Phosphatidylinositol­3 kinases, PI3Ks, constitute a lipid kinase family characterized by their ability tophosphorylate inositol ring 3'­OH group in inositol phospholipids to generate the second messengerphosphatidylinositol­3,4,5­trisphosphate (PI­3,4,5­P(3)). RPTK activation results in PI(3,4,5)P(3) andPI(3,4)P(2) production by PI3K at the inner side of the plasma membrane. Akt interacts with thesephospholipids, causing its translocation to the inner membrane, where it is phosphorylated and activatedby PDK1 and PDK2. Read More

2004Apr

Similar Publications

Doomed trials for promising adenoviruses: a rationale for success.

J. Clin. Oncol.J Clin Oncol 2004 Mar;22(6):1162­3; author reply 1163­4Enrique Casado, Javier De Castro, Cristóbal Belda­Iniesta, Jaime Feliu,Manuel González­Barón, Waleed Arafat

2004Mar

1/10/2016 Publications Authored by Cristobal Belda­Iniesta

http://www.pubfacts.com/author/Cristobal+Belda­Iniesta 20/20

Read More

Similar Publications

Eicosapentaenoic acid as a targeted therapy for cancer cachexia.

J. Clin. Oncol.J Clin Oncol 2003 Dec;21(24):4657­8; author reply 4658Cristobal Belda­Iniesta, Javier de Castro Carpeno, Juan Angel Fresno Vara, Paloma Cejas Guerrero, Enrique CasadoSaenz, Enrique Espinosa Arranz, Andres Redondo Sanchez, Jaime Feliu Battle, Manuel Gonzalez Baron

Read More

2003Dec

Similar Publications

Re: Folliculitis associated with weekly paclitaxel treatment.

J. Natl. Cancer Inst.J Natl Cancer Inst 2003 Mar;95(5):410Cristobal Belda­Iniesta, Enrique Casado, Miriam Corral de la Calle,Beatriz Castelo, Manuel González Barón

2003Mar